Invitation to presentation of Isofol´s report for the fourth quarter of 2022
GOTHENBURG, Sweden, February 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for […]
Other Corporate Information
Isofol has obtained a request to call for an extraordinary general meeting
GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an
Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday called shareholders to an extraordinary
Isofol Medical’s Board of Directors intends to call an extraordinary general meeting with proposals for dividends and liquidation of the company
GOTHENBURG, Sweden, January 19, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), decided today to call an extraordinary general
Final data from the AGENT study confirms topline results
GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT
Invitation to presentation of Isofol’s report for the third quarter of 2022
GOTHENBURG, Sweden, October 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofol reports data from the AGENT study
GOTHENBURG, Sweden, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported data from the AGENT study
Isofol provides update on the AGENT study
GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to
Invitation to presentation of Isofol´s report for the second quarter of 2022
GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints
GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the